Axsome Therapeutics Clocks Around 60% Topline Growth In Q1

Why did Warren Buffett step down from Berkshire Hathaway? How will Trump's 100% foreign film tariffs impact Hollywood? What caused Tesla's stock decline in Europe? Why are states suing Trump over wind energy policies? How is the Fed likely to act on interest rates this week? What are the effects of OPEC+ increasing oil production? How will Apple’s App Store fee ruling appeal affect developers? Why is Skechers being taken private amid trade tensions? What is the impact of student loan collections resuming?

Axsome Therapeutics Clocks Around 60% Topline Growth In Q1

benzinga.com/25/05/45196924/neurology-focused-axsome-therapeutics-clocks-around-60-topline-growth-in-q1-commercial-availability-of-newly-appr

Axsome Therapeutics Inc (NASDAQ:AXSM) on Monday reported first-quarter 2025 revenues of $121.5 million, up from $75 million a year ago, beating the consensus of $119.87 million.
Auvelity (oral antidepressant) net product sales for the quarter were $96.2 million, up 80% year over…

This story appeared on benzinga.com, 2025-05-05 14:41:49.